Evoke Pharma Stock Current Ratio
| EVOK Stock | USD 4.33 0.17 3.78% |
Evoke Pharma fundamentals help investors to digest information that contributes to Evoke Pharma's financial success or failures. It also enables traders to predict the movement of Evoke Stock. The fundamental analysis module provides a way to measure Evoke Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evoke Pharma stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 2.25 | 2.14 |
Evoke | Current Ratio |
Evoke Pharma Company Current Ratio Analysis
Evoke Pharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Evoke Pharma Current Ratio | 10.65 X |
Most of Evoke Pharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evoke Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Evoke Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Evoke Pharma is extremely important. It helps to project a fair market value of Evoke Stock properly, considering its historical fundamentals such as Current Ratio. Since Evoke Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Evoke Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Evoke Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Evoke Current Ratio Historical Pattern
Today, most investors in Evoke Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Evoke Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Evoke Pharma current ratio as a starting point in their analysis.
Evoke Pharma Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Evoke Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Evoke Pharma has a Current Ratio of 10.65 times. This is 265.98% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Evoke Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evoke Pharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Evoke Pharma could also be used in its relative valuation, which is a method of valuing Evoke Pharma by comparing valuation metrics of similar companies.Evoke Pharma is currently under evaluation in current ratio category among its peers.
Evoke Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Evoke Pharma from analyzing Evoke Pharma's financial statements. These drivers represent accounts that assess Evoke Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Evoke Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 36.1M | 65.8M | 17.7M | 8.4M | 3.5M | 3.3M | |
| Enterprise Value | 30.6M | 63.0M | 13.6M | 3.7M | 3.8M | 3.6M |
Evoke Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Evoke Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Evoke Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Evoke Fundamentals
| Return On Equity | -3.5 | ||||
| Return On Asset | -0.33 | ||||
| Profit Margin | (0.71) % | ||||
| Operating Margin | (0.48) % | ||||
| Current Valuation | 348.01 K | ||||
| Shares Outstanding | 1.49 M | ||||
| Shares Owned By Insiders | 4.59 % | ||||
| Shares Owned By Institutions | 17.12 % | ||||
| Number Of Shares Shorted | 101.01 K | ||||
| Price To Earning | (3.21) X | ||||
| Price To Book | 1.52 X | ||||
| Price To Sales | 0.78 X | ||||
| Revenue | 5.18 M | ||||
| Gross Profit | 2.14 M | ||||
| EBITDA | (7.29 M) | ||||
| Net Income | (7.79 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 4.02 X | ||||
| Total Debt | 5 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 10.65 X | ||||
| Book Value Per Share | 4.90 X | ||||
| Cash Flow From Operations | (4.98 M) | ||||
| Short Ratio | 0.11 X | ||||
| Earnings Per Share | (10.13) X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 18.0 | ||||
| Beta | 0.35 | ||||
| Market Capitalization | 6.69 M | ||||
| Total Asset | 7.07 M | ||||
| Retained Earnings | (123.44 M) | ||||
| Working Capital | 3.79 M | ||||
| Current Asset | 9.52 M | ||||
| Current Liabilities | 1.83 M | ||||
| Net Asset | 7.07 M |
About Evoke Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evoke Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evoke Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evoke Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Evoke Pharma Piotroski F Score and Evoke Pharma Altman Z Score analysis. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.13) | Revenue Per Share 7.792 | Quarterly Revenue Growth 0.698 | Return On Assets (0.34) | Return On Equity (3.50) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.